PL2265251T3 - Kompozycje farmaceutyczne posiadające pożądaną biodostępność - Google Patents

Kompozycje farmaceutyczne posiadające pożądaną biodostępność

Info

Publication number: PL2265251T3
Authority: PL; Poland
Prior art keywords: pharmaceutical compositions; desirable bioavailability; bioavailability; desirable; pharmaceutical
Prior art date: 2008-03-17

Application number

PL09722278T

Other languages

English (en)

Inventor

Bhagwati P Kabra

Nuria Carreras

Mónica Cuchi

Francisco Javier Galán

Mridvika

Elena González Puig

Nuria Jiménez

Carmen Martínez

Original Assignee

Alcon Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-17

Filing date

2009-03-13

Publication date

2015-10-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41037889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2265251(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-13 Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd

2015-10-30 Publication of PL2265251T3 publication Critical patent/PL2265251T3/pl

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL09722278T 2008-03-17 2009-03-13 Kompozycje farmaceutyczne posiadające pożądaną biodostępność PL2265251T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US3711708P	2008-03-17	2008-03-17
US11192008P	2008-11-06	2008-11-06
EP09722278.0A EP2265251B1 (en)	2008-03-17	2009-03-13	Pharmaceutical compositions having desirable bioavailability
PCT/US2009/037077 WO2009117316A2 (en)	2008-03-17	2009-03-13	Pharmaceutical compositions having desirable bioavailability

Publications (1)

Publication Number	Publication Date
PL2265251T3 true PL2265251T3 (pl)	2015-10-30

Family

ID=41037889

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09722278T PL2265251T3 (pl)	2008-03-17	2009-03-13	Kompozycje farmaceutyczne posiadające pożądaną biodostępność

Country Status (24)

Country	Link
US (5)	US20090234004A1 (pl)
EP (4)	EP3042646B1 (pl)
JP (2)	JP5654444B2 (pl)
KR (1)	KR101586357B1 (pl)
CN (2)	CN101977588A (pl)
AR (1)	AR070888A1 (pl)
AU (1)	AU2009225824B2 (pl)
BR (1)	BRPI0908717B1 (pl)
CA (1)	CA2716994C (pl)
CL (1)	CL2009000624A1 (pl)
DE (2)	DE202009019087U1 (pl)
DK (3)	DK2599475T3 (pl)
ES (3)	ES2542728T3 (pl)
HK (1)	HK1212605A1 (pl)
HU (1)	HUE025619T2 (pl)
MX (1)	MX2010009570A (pl)
PL (1)	PL2265251T3 (pl)
PT (1)	PT2265251E (pl)
RU (1)	RU2503453C2 (pl)
SI (1)	SI2265251T1 (pl)
TW (1)	TWI544927B (pl)
UY (1)	UY31716A1 (pl)
WO (1)	WO2009117316A2 (pl)
ZA (1)	ZA201006227B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI544927B (zh) *	2008-03-17	2016-08-11	愛爾康研究有限公司	具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
PT2254549E (pt)	2008-03-17	2014-01-30	Alcon Res Ltd	Composições farmacêuticas aquosas que contêm complexos de borato-poliol
TWI489997B (zh)	2009-06-19	2015-07-01	Alcon Res Ltd	含有硼酸－多元醇錯合物之水性藥學組成物
CN103140215A (zh) *	2010-07-21	2013-06-05	爱尔康研究有限公司	具有提高的溶解度特征的药物组合物
EP2452669A1 (en)	2010-10-29	2012-05-16	Omnivision GmbH	Ophthalmic composition
HK1211867A1 (en)	2012-08-24	2016-06-03	Sun Pharma Global Fze	Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
ES2838756T3 (es) *	2014-01-24	2021-07-02	Sentiss Pharma Private Ltd	Composición farmacéutica que comprende brinzolamida
EP2937076B1 (en) *	2014-04-25	2019-09-11	Alfred E. Tiefenbacher (GmbH & Co. KG)	Eye drops containing prostaglandin and tyloxapol
CA2949954A1 (en) *	2014-05-23	2015-11-26	Ocular Technologies Sarl	Topical formulations and uses thereof
EP3209331B1 (en)	2014-10-20	2023-07-12	Sentiss Pharma Private Limited	Ophthalmic solution
US11458041B2 (en)	2015-10-08	2022-10-04	Ocular Therapeutix, Inc.	Punctal plug and bioadhesives
WO2017083167A1 (en)	2015-11-10	2017-05-18	Ocular Technologies Sarl	Topical formulations and uses thereof
WO2017083410A1 (en) *	2015-11-12	2017-05-18	Ocular Technologies Sarl	Topical formulations and uses thereof
RU2747455C2 (ru)	2016-02-29	2021-05-05	Сан Фарма Глобал Фзе	Циклоспорин-содержащие лекарственные формы для наружного применения и их применения
PT3861985T (pt)	2020-02-06	2023-08-03	Ocular Therapeutix Inc	Composições e métodos para tratar doenças oculares
EP4142664A4 (en)	2020-04-27	2024-05-29	Ocular Therapeutix, Inc.	METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
TWI819317B (zh) *	2021-06-07	2023-10-21	溫士頓醫藥股份有限公司	含前列腺素衍生物的眼用奈米乳劑組合物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3711708A (en)	1971-02-25	1973-01-16	Optical Coating Laboratory Inc	Rapid scan identifier for use in infrared absorption spectroscopy
US3931319A (en)	1974-10-29	1976-01-06	Millmaster Onyx Corporation	Capped polymers
US4027020A (en)	1974-10-29	1977-05-31	Millmaster Onyx Corporation	Randomly terminated capped polymers
GB2084870B (en)	1980-10-10	1985-05-09	Muhlemann R Hans	Oral compositions containing pyrimidine amine compounds and zinc salts
US4407791A (en)	1981-09-28	1983-10-04	Alcon Laboratories, Inc.	Ophthalmic solutions
US4525346A (en)	1981-09-28	1985-06-25	Alcon Laboratories, Inc.	Aqueous antimicrobial ophthalmic solutions
US4836986A (en)	1984-09-28	1989-06-06	Bausch & Lomb Incorporated	Disinfecting and preserving systems and methods of use
US5037647A (en)	1988-09-15	1991-08-06	Alcon Laboratories, Inc.	Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5145643A (en)	1990-01-05	1992-09-08	Allergan, Inc.	Nonoxidative ophthalmic compositions and methods for preserving and using same
US5221664A (en) *	1990-04-23	1993-06-22	Magainin Pharmaaceuticals Inc.	Composition and treatment with biologically active peptides and toxic cations
US5422073A (en)	1990-12-27	1995-06-06	Allergan, Inc.	Method and composition for disinfecting contact lenses
US5932572A (en)	1992-02-21	1999-08-03	Alcon Laboratories, Inc.	Topical anti-glaucoma compositions
US5505953A (en)	1992-05-06	1996-04-09	Alcon Laboratories, Inc.	Use of borate-polyol complexes in ophthalmic compositions
US5300287A (en)	1992-11-04	1994-04-05	Alcon Laboratories, Inc.	Polymeric antimicrobials and their use in pharmaceutical compositions
US5320843A (en)	1992-12-10	1994-06-14	Polymer Technology Corporation	Method for improving antibacterial properties of ophthalmic solutions
WO1996003158A1 (en)	1994-07-22	1996-02-08	Alcon Laboratories, Inc.	Use of low molecular weight amino acids in ophthalmic compositions
US5603929A (en) *	1994-11-16	1997-02-18	Alcon Laboratories, Inc.	Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US5631287A (en) *	1994-12-22	1997-05-20	Alcon Laboratories, Inc.	Storage-stable prostaglandin compositions
US6011062A (en)	1994-12-22	2000-01-04	Alcon Laboratories, Inc.	Storage-stable prostaglandin compositions
WO1996029049A1 (en)	1995-03-20	1996-09-26	Unilever Plc	Liquid cleansing formulations
HU225329B1 (en)	1996-09-12	2006-09-28	Richter Gedeon Vegyeszet	Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
EP0948333A1 (en) *	1996-11-01	1999-10-13	Alcon Laboratories, Inc.	Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma
GB9624928D0 (en)	1996-11-29	1997-01-15	Lintrend Developments Ni Ltd	Fibrous products and their production
US6071904A (en)	1996-12-11	2000-06-06	Alcon Laboratories, Inc.	Process for manufacturing ophthalmic suspensions
WO1998025649A1 (en)	1996-12-13	1998-06-18	Alcon Laboratories, Inc.	Use of low molecular weight amino alcohols in ophthalmic compositions
AR002194A1 (es)	1997-03-17	1998-01-07	Sanchez Reynaldo Alemany	Instrumento computarizado para el analisis del movimiento.
WO1998053809A1 (en)	1997-05-30	1998-12-03	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
BR9906597A (pt) *	1998-07-14	2000-07-18	Alcon Lab Inc	Produto de prostaglandina
US6235781B1 (en) *	1998-07-14	2001-05-22	Alcon Laboratories, Inc.	Prostaglandin product
US6034043A (en) *	1999-04-20	2000-03-07	Lever Brothers Company, Division Of Conopco, Inc.	Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en)	1999-05-25	2002-11-19	The Regents Of The University Of California	Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US20020009507A1 (en)	2000-01-19	2002-01-24	Alcon Universal Ltd.	Use of polyethoxylated castor oil for the treatment of dry eye
DK1321144T3 (da) *	2000-09-13	2011-03-07	Santen Pharmaceutical Co Ltd	Øjendråber
CN1477929A (zh)	2000-11-29	2004-02-25	��˹��ŵ��	水性消毒系统
JP2002332225A (ja) *	2001-05-09	2002-11-22	Lion Corp	眼科用組成物
DE10222388A1 (de)	2001-05-22	2003-02-13	Denso Corp	Kompressor mit veränderbarer Verdrängung
US6743439B1 (en) *	2001-06-27	2004-06-01	Alcon, Inc.	Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
JP4863589B2 (ja)	2001-09-28	2012-01-25	ロート製薬株式会社	水性組成物
CA2707068A1 (en)	2002-09-09	2004-03-18	Santen Pharmaceutical Co., Ltd.	Clear ophthalmic solution comprising latanoprost as active ingredient
US7074827B2 (en)	2002-10-24	2006-07-11	Sucampo Ag (Usa) Inc.	Method for treating ocular hypertension and glaucoma
ATE450264T1 (de)	2003-07-31	2009-12-15	Santen Pharmaceutical Co Ltd	Prostaglandin enthaltendes produkt
JP4453815B2 (ja) *	2003-12-08	2010-04-21	ライオン株式会社	ドライアイ治療剤
JP2005247801A (ja) *	2004-03-08	2005-09-15	Zeria Pharmaceut Co Ltd	安定な点眼剤
CA2563365A1 (en)	2004-04-23	2005-11-03	Mystic Pharmaceuticals, Inc.	Multiple unit dose drug delivery system
GB0501192D0 (en)	2005-01-20	2005-03-02	Resolution Chemicals Ltd	Stable prostaglandin-containing compositions
US7851504B2 (en)	2005-03-16	2010-12-14	Allergan, Inc.	Enhanced bimatoprost ophthalmic solution
WO2008042619A2 (en)	2006-09-28	2008-04-10	Alcon Research, Ltd.	Self-preserved aqueous pharmaceutical compositions
WO2008052037A2 (en)	2006-10-24	2008-05-02	Alcon Research, Ltd.	Packaging materials for formulations containing 2-pyrrolidone derivatives
US20080095863A1 (en)	2006-10-24	2008-04-24	Alcon Manufacturing Ltd.	2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
WO2008096804A1 (ja) *	2007-02-07	2008-08-14	Teika Pharmaceutical Co., Ltd.	ラタノプロスト含有点眼剤
TWI544927B (zh) *	2008-03-17	2016-08-11	愛爾康研究有限公司	具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en)	2008-05-30	2009-12-02	Santen Pharmaceutical Co., Ltd	Method and composition for treating ocular hypertension and glaucoma
EP4434392A3 (en)	2019-05-31	2024-12-18	Karsten Manufacturing Corporation	Golf bag convertible strap assembly

2009
- 2009-03-12 TW TW098108014A patent/TWI544927B/zh active
- 2009-03-13 EP EP15202422.0A patent/EP3042646B1/en not_active Revoked
- 2009-03-13 EP EP09722278.0A patent/EP2265251B1/en not_active Revoked
- 2009-03-13 US US12/403,543 patent/US20090234004A1/en not_active Abandoned
- 2009-03-13 BR BRPI0908717-6A patent/BRPI0908717B1/pt active IP Right Grant
- 2009-03-13 ES ES09722278.0T patent/ES2542728T3/es active Active
- 2009-03-13 DE DE202009019087.0U patent/DE202009019087U1/de not_active Expired - Lifetime
- 2009-03-13 EP EP13184332.8A patent/EP2705836A1/en not_active Withdrawn
- 2009-03-13 KR KR1020107022614A patent/KR101586357B1/ko active Active
- 2009-03-13 CN CN2009801092915A patent/CN101977588A/zh active Pending
- 2009-03-13 SI SI200931225T patent/SI2265251T1/sl unknown
- 2009-03-13 AU AU2009225824A patent/AU2009225824B2/en active Active
- 2009-03-13 DK DK12193597.7T patent/DK2599475T3/en active
- 2009-03-13 WO PCT/US2009/037077 patent/WO2009117316A2/en not_active Ceased
- 2009-03-13 DK DK15202422.0T patent/DK3042646T3/en active
- 2009-03-13 JP JP2011500876A patent/JP5654444B2/ja active Active
- 2009-03-13 EP EP12193597.7A patent/EP2599475B1/en active Active
- 2009-03-13 AR ARP090100905A patent/AR070888A1/es not_active Application Discontinuation
- 2009-03-13 PT PT97222780T patent/PT2265251E/pt unknown
- 2009-03-13 CN CN201510501617.6A patent/CN105012964A/zh active Pending
- 2009-03-13 MX MX2010009570A patent/MX2010009570A/es active IP Right Grant
- 2009-03-13 RU RU2010142307/15A patent/RU2503453C2/ru active
- 2009-03-13 HU HUE09722278A patent/HUE025619T2/en unknown
- 2009-03-13 PL PL09722278T patent/PL2265251T3/pl unknown
- 2009-03-13 ES ES12193597.7T patent/ES2635197T3/es active Active
- 2009-03-13 DE DE202009019114.1U patent/DE202009019114U1/de not_active Expired - Lifetime
- 2009-03-13 CA CA2716994A patent/CA2716994C/en not_active Expired - Fee Related
- 2009-03-13 ES ES15202422.0T patent/ES2637028T3/es active Active
- 2009-03-13 DK DK09722278.0T patent/DK2265251T3/en active
- 2009-03-13 US US12/403,529 patent/US8178582B2/en active Active
- 2009-03-16 UY UY031716A patent/UY31716A1/es not_active Application Discontinuation
- 2009-03-16 CL CL2009000624A patent/CL2009000624A1/es unknown
2010
- 2010-08-31 ZA ZA2010/06227A patent/ZA201006227B/en unknown
2011
- 2011-10-04 US US13/252,255 patent/US8722735B2/en active Active
2012
- 2012-04-09 US US13/442,475 patent/US8754123B2/en active Active
2013
- 2013-10-23 JP JP2013219982A patent/JP2014012744A/ja not_active Withdrawn
2014
- 2014-05-01 US US14/267,668 patent/US9144561B2/en active Active
2016
- 2016-01-19 HK HK16100544.3A patent/HK1212605A1/zh unknown

Also Published As

Publication number	Publication date
CA2716994C (en)	2013-05-28
US8754123B2 (en)	2014-06-17
US8722735B2 (en)	2014-05-13
EP3042646B1 (en)	2017-05-10
MX2010009570A (es)	2010-09-28
DK2265251T3 (en)	2015-06-29
HK1220378A1 (en)	2017-05-05
US20090234004A1 (en)	2009-09-17
DE202009019114U1 (de)	2016-08-01
US20120029073A1 (en)	2012-02-02
US9144561B2 (en)	2015-09-29
TW200940068A (en)	2009-10-01
RU2503453C2 (ru)	2014-01-10
BRPI0908717B1 (pt)	2021-12-21
EP2599475A2 (en)	2013-06-05
WO2009117316A2 (en)	2009-09-24
CN105012964A (zh)	2015-11-04
HK1212605A1 (zh)	2016-06-17
KR101586357B1 (ko)	2016-01-18
JP2014012744A (ja)	2014-01-23
EP2599475B1 (en)	2017-04-26
RU2010142307A (ru)	2012-04-27
DE202009019087U1 (de)	2016-05-20
CA2716994A1 (en)	2009-09-24
EP2599475A3 (en)	2013-08-21
US20140243409A1 (en)	2014-08-28
DK3042646T3 (en)	2017-08-28
KR20110005801A (ko)	2011-01-19
US20090234013A1 (en)	2009-09-17
EP2705836A1 (en)	2014-03-12
EP2265251A2 (en)	2010-12-29
JP5654444B2 (ja)	2015-01-14
US20120245227A1 (en)	2012-09-27
AU2009225824A1 (en)	2009-09-24
TWI544927B (zh)	2016-08-11
JP2011514384A (ja)	2011-05-06
WO2009117316A3 (en)	2010-09-10
ZA201006227B (en)	2012-02-29
ES2635197T3 (es)	2017-10-02
ES2637028T3 (es)	2017-10-10
EP3042646A1 (en)	2016-07-13
HUE025619T2 (en)	2016-04-28
SI2265251T1 (sl)	2015-08-31
UY31716A1 (es)	2009-08-31
CN101977588A (zh)	2011-02-16
AR070888A1 (es)	2010-05-12
EP2265251B1 (en)	2015-05-27
DK2599475T3 (en)	2017-08-21
CL2009000624A1 (es)	2010-01-04
ES2542728T3 (es)	2015-08-10
US8178582B2 (en)	2012-05-15
AU2009225824B2 (en)	2014-04-10
PT2265251E (pt)	2015-09-01
BRPI0908717A2 (pt)	2020-12-01

Publication	Publication Date	Title
ZA201006227B (en)	2012-02-29	Pharmaceutical compositions having desirable bioavailability
GB0814695D0 (en)	2008-09-17	Pharmaceutical compositions
IL247741A0 (en)	2016-11-30	pharmaceutical preparations
PT2323623T (pt)	2016-11-04	Composições farmacêuticas
EP2227085A4 (en)	2013-10-09	INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
SG2014015093A (en)	2014-04-28	Pharmaceutical compositions
EP2222313A4 (en)	2011-02-16	PHARMACEUTICAL COMPOSITIONS
GB0707127D0 (en)	2007-05-23	Pharmaceutical compositions
EP2146695A4 (en)	2010-05-19	PHARMACEUTICAL COMPOSITIONS
GB0709811D0 (en)	2007-07-04	Pharmaceutical compositions
IL206487A0 (en)	2010-12-30	Pharmaceutical compositions
GB0712454D0 (en)	2007-08-08	Pharmaceutical compositions
IL219018A0 (en)	2012-06-28	Pharmaceutical compositions
GB0800659D0 (en)	2008-02-20	Pharmaceutical Compositions
GB2454923B (en)	2011-04-20	Pharmaceutical compositions
IL201394A0 (en)	2010-05-31	Niacin - based pharmaceutical compositions
GB0806283D0 (en)	2008-05-14	Pharmaceutical compositions
GB0802024D0 (en)	2008-03-12	Pharmaceutical compositions
GB0806156D0 (en)	2008-05-14	Pharmaceutical compositions
EP2308842A4 (en)	2012-03-14	PHARMACEUTICAL COMPOSITIONS
GB0804485D0 (en)	2008-04-16	Novel pharmaceutical compositions
GB0805807D0 (en)	2008-04-30	Novel pharmaceutical compositions
GB0706657D0 (en)	2007-05-16	Pharmaceutical compositions
GB0709603D0 (en)	2007-06-27	Pharmaceutical compositions
GB0813395D0 (en)	2008-08-27	Local pharmaceutical compositions